Combination of Olaparib and Navitoclax in Women With HGSC and TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: High Grade Serous Carcinoma|Triple Negative Breast Cancer|Ovarian Cancer
Interventions: DRUG: Olaparib tablet|DRUG: Navitoclax
Sponsor: Sunnybrook Health Sciences Centre
Collaborators: Exactis Innovation|Centre hospitalier de l'Université de Montréal (CHUM)|Princess Margaret Hospital, Canada